CoChat

Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells

Open access
Kopecka, Joanna, Campia, Ivana, Jacobs, Andrea, Frei, Andreas P., Ghigo, Dario, Wollscheid, Bernd, Riganti, Chiara · 2015 · Oncotarget
Cited by 117

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

// Joanna Kopecka 1, * , Ivana Campia 1, * , Andrea Jacobs 2 , Andreas P. Frei 2, 3 , Dario Ghigo 1 , Bernd Wollscheid 2, 3 , Chiara Riganti 1 1 Department of Oncology, University of Torino, 10126 Torino, Italy 2 Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland 3 Biomedical Proteomics Platform (BMPP), Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland * These authors have contributed equally to this work Correspondence to: Chiara Riganti, e-mail: chiara.riganti@unito.it Keywords: chemoresistance, surfaceome, P-glycoprotein, carbonic anhydrase type XII Received: September 09, 2014 Accepted: December 09, 2014 Published: February 18, 2015 ABSTRACT Multidrug resistance (MDR) in cancer cells is a challenging phenomenon often associated with P-glycoprotein (Pgp) surface expression. Finding new ways to bypass Pgp-mediated MDR still remains a daunting challenge towards the successful treatment of malignant neoplasms such as colorectal cancer. We applied the Cell Surface Capture technology to chemosensitive and chemoresistant human colon cancer to explore the cell surface proteome of Pgp-expressing cells in a discovery-driven fashion. Comparative quantitative analysis of identified cell surface glycoproteins revealed carbonic anhydrase type XII (CAXII) to be up-regulated on the surface of chemoresistant cells, similarly to Pgp. In cellular models showing an acquired MDR phenotype due to the selective pressure of chemotherapy, the progressive increase of the transcription factor hypoxia-inducible factor-1 alpha was paralleled by the simultaneous up-regulation of Pgp and CAXII. CAXII and Pgp physically interacted at the cell surface. CAXII silencing or pharmacological inhibition with acetazolamide decreased the ATPase activity of Pgp by altering the optimal pH at which Pgp operated and promoted chemosensitization to Pgp substrates in MDR cells. We propose CAXII as a new secondary marker of the MDR phenotype that influences Pgp activity directly and can be used as a pharmacological target for MDR research and potential treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2882

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 117

Metadata

Authors
Kopecka, J., Campia, I., Jacobs, A., Frei, A. P., Ghigo, D., Wollscheid, B., & Riganti, C.
Venue
Oncotarget
Published
2015-02-18
Volume
6
Issue
9
Pages
6776-6793
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1509146666
Cited by
117
References
3
FWCI
3.73
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.2882
The paper
Kopecka, J., Campia, I., Jacobs, A., Frei, A. P., Ghigo, D., Wollscheid, B., & Riganti, C. (2015). Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.2882

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.